

## Special Issue

# New Trends and Challenges in Pharmacogenomics Research

### Message from the Guest Editor

The field of pharmacogenomics is rapidly growing due to major advancements in sequencing technology. While pharmacogenomics has shown promise in reducing the burden of drug adverse events, the adoption of pharmacogenomics into routine practice has been lagging. Compounded by the limited sample size, the role of pharmacogenomics in early drug development programs remains limited to fully characterize the effect of genetic variability on drug response.

This Special Issue aims to highlight the trends, barriers, and opportunities to move pharmacogenomics from the bench to bed and back again. When shifting from a single gene variant to a polygenic risk assessment to predict the response, novel approaches to account for common and rare variants to assess the patient's overall response are needed. These approaches will likely be able to optimize patient treatment outcomes as well as the selection of patients in clinical trials. We welcome the submission of both research and review articles to this Special Issue.

### Guest Editor

Prof. Dr. Youssef Roman

Department of Pharmacy Practice and Administrative Sciences, L.S. Skaggs College of Pharmacy, Idaho State University, 1311 E Central Dr, Meridian, ID 83642, USA

### Deadline for manuscript submissions

31 May 2026



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/224583](https://mdpi.com/si/224583)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).